![EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for DEXYCU - Ophthalmology Breaking News EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for DEXYCU - Ophthalmology Breaking News](https://ophthalmologybreakingnews.com/files/images/blog_eyepoint-pharmaceuticals-and-imprimisrx-announce-us-commercial-alliance-for-dexycu.jpg)
EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for DEXYCU - Ophthalmology Breaking News
![ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery](https://mma.prnewswire.com/media/167712/imprimis_pharmaceuticals_logo.jpg?p=twitter)
ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery
![Imprimis Pharmaceuticals Patent-Pending Dropless and LessDrops Formulations Exceed One Million Patient Eyes Milestone Imprimis Pharmaceuticals Patent-Pending Dropless and LessDrops Formulations Exceed One Million Patient Eyes Milestone](https://mma.prnewswire.com/media/539683/LessDrops.jpg?p=facebook)